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Retinoic acid increases the effect of 
bone morphogenetic protein type 2 on 
osteogenic differentiation of human 
adipose-derived stem cells
Bone morphogenetic protein type 2 (BMP-2) and retinoic acid (RA) are 
osteoinductive factors that stimulate endogenous mechanisms of bone 
repair which can be applied on management of osseous defects in oral and 
maxillofacial fields. Objective: Considering the different results of RA on 
osteogenesis and its possible use to substitute/potency BMP-2 effects, this 
study evaluated the outcomes of BMP-2, RA, and BMP-2+RA treatments 
on in vitro osteogenic differentiation of human adipose-derived stem cells 
(ASCs) and the signaling pathway(s) involved. Material and Methods: ASCs 
were treated every other day with basic osteogenic medium (OM) alone or 
supplemented with BMP-2, RA, or BMP-2+RA. Alkaline phosphatase (ALP) 
activity was determined using the r-nitrophenol method. Extracellular 
matrix mineralization was evaluated using von Kossa staining and calcium 
quantification. Expression of osteonectin and osteocalcin mRNA were 
determined using qPCR. Smad1, Smad4, phosphorylated Smad1/5/8, BMP-
4, and BMP-7 proteins expressions were analyzed using western blotting. 
Signaling pathway was evaluated using the IPA® software. Results: RA 
promoted the highest ALP activity at days 7, 14, 21, and 28, in comparison 
to BMP-2 and BMP-2+RA. BMP-2+RA best stimulated phosphorylated 
Smad1/5/8 protein expression at day 7 and Smad4 expression at days 7, 
14, 21, and 28. Osteocalcin and osteonectin mRNA expressions were best 
stimulated by BMP-2+RA at day 7. Matrix mineralization was most improved 
by BMP-2+RA at days 12 and 32. Additionally, BMP-2+RA promoted the 
highest BMP signaling pathway activation at days 7 and 14, and demonstrated 
more activation of differentiation of bone-forming cells than OM alone. 
Conclusions: In summary, RA increased the effect of BMP-2 on osteogenic 
differentiation of human ASCs. 
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Introduction
The repair of extensive bone defects remains a 
challenge in Dentistry. Given the drawbacks of the 
available bone graft materials, scientists have been 
searching for new substances and combinations to be 
used as osteoinductive factors. Bone morphogenetic 
proteins (BMPs) belong to the transforming growth 
factor (TGF) super-family and were initially identified 
by their ability to induce ectopic bone formation.1 
BMP type 2 (BMP-2) is one of the most studied 
osteoinductive factors that has been used for 
osteogenic differentiation of mesenchymal stem cells 
for bone repair in oral and maxillofacial surgeries.2,3 
However, in addition to its high cost, BMP-2 use has 
been related with adverse effects such as substantial 
swelling, erythema, and pain.4-6
Retinoic acid (RA) is a vitamin A-derived compound 
that is critical in embryonic development and 
maintenance of vital organs in adults.7 Some in 
vitro studies have shown that RA is involved in 
up-regulation of osteogenic genes, increasing 
osteogenic differentiation of different cell types 
including osteosarcoma-derived cells, osteoblasts, 
preadipocytes, and mesenchymal stem cells.8-11 RA 
has also been related to the enhancement of BMP-
2 effects by increasing alkaline phosphatase (ALP) 
activity, RunX2 transcription factor, and osteopontin 
mRNA expression during chondrocytic and osteoblastic 
differentiation of mouse cells.12,13 Moreover, Cowan, 
et al.14 (2005) demonstrated that BMP-2 combined 
with RA accelerates in vivo bone formation. However, 
the outcomes of RA, alone or combined with BMP-2, 
on osteogenic differentiation are controversial, since 
Wang, et al.15 (2008) demonstrated that RA inhibits 
osteogenic differentiation of rat bone marrow stromal 
cells, Ogston, et al.16 (2002) and Takahashi, et al.17 
(2008) showed a reduction on ALP activity by RA, 
and Hoffman, et al.18 (2006) verified that BMP action 
involves attenuation of RA signaling. Considering the 
different results of RA on osteogenic induction and its 
possible use to substitute/potency the BMP-2 effects, 
this study aimed to evaluate the effects of RA and 
BMP-2, alone or combined, on in vitro osteogenic 
differentiation of human adipose-derived stem cells 
(ASCs) and the signaling pathway(s) involved in the 
differentiation process.
Materials and methods
Reagents
Antibiotics/antifungicides (PSA) were purchased 
from Cultilab (São Paulo, SP, Brazil). All-trans retinoic 
acid, ascorbate, β-glycerophosphate, BMP-2, eosin, 
paraformaldehyde, ρ-nitrophenol phosphate (ρNPP), 
silver nitrate, and trypsin were obtained from Sigma-
Aldrich (St. Louis, MO, USA). α-modified Eagle’s 
minimal essential medium (αMEM modified) and 
Dulbecco’s modified Eagle’s medium (DMEM) were 
acquired from Nutricell (São Paulo, SP, Brazil). DNAse, 
fetal bovine serum (FBS), SuperScript™ III, and 
Trizol® were purchased from Invitrogen (Carlsbad, CA, 
USA). Calcium Assay Kit was obtained from BioAssay 
Systems (Hayward, CA, USA). SYBR® Green PCR 
Master Mix was purchased from Applied Biosystems 
(Carlsbad, CA, USA). Immobilon-P membranes and the 
antibodies anti-β-actin (04-1116), -Smad1 (05-1459), 
-phosphorylated Smad1/5/8 (AB3848), -Smad4 (04-
1033),  BMP-4 (MAB1049), -BMP-7 (MAB4350), -rabbit, 
and -mouse were obtained from Millipore (Danvers, 
MA, USA). Enhanced chemiluminescence Pierce ECL 
was purchased from Thermo scientific (Rockford, IL, 
USA). All chemicals were analytical grade.
Adipose-derived stem cells (ASCs) isolation 
and cell culture conditions
Approval from the Human Ethics Committee of the 
Universidade Federal de Santa Catarina and written 
consent from all participants were obtained before 
commencement of this study (No. 194/06 for ASCs 
and No. 568/10 for osteoblasts). Human lipoaspirate 
tissues from healthy patients (mean age 21), with 
normal body mass indexes, non-smokers and not 
taking any medication were processed to isolate ASCs, 
as previously described.19 ASCs were maintained at 
sub-confluent levels and used at passage 3 for all 
experiments. ASCs were treated every other day, 
according to the groups: OM – osteogenic medium 
(DMEM, 10% FBS, 1% PSA, 250 µM ascorbate, and 
10 mM β-glycerophosphate); BMP-2 – OM and 50 ng/
ml BMP-2; RA – OM and 2.5 µM all-trans retinoic acid 
(RA); BMP-2+RA – OM, 50 ng/ml BMP-2, and 2.5 µM 
RA.12 Human osteoblasts isolated from biopsies of 
mandibular cortical bone20 were maintained in OM 
and used at passage 6 as positive control in qPCR 
experiments. MC3T3-E1 pre-osteoblasts subclone 4 
(American Type Culture Collection, Manassas, VA, 
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USA) were used as positive controls in ALP activity, 
matrix mineralization, and western blotting assays. 
MC3T3-E1 cells were cultured according to the 
supplier’s recommendations in αMEM modified with 5 
µM ascorbate and 10 mM β-glycerophosphate.
Immunopheno typ ing  and  mu l t i l i neage 
differentiation of ASCs were performed to confirm the 
mesenchymal stem cells characteristics, as previously 
described.19
Determination of alkaline phosphatase activity
ASCs and MC3T3-E1 (9.4x104 cells/well) were 
cultured in 24-well plates for 7, 14, 21, and 28 
days. ALP activity was determined by releasing 
ρ-nitrophenol (ρNP) from ρ-nitrophenol phosphate 
(ρNPP) as previously described.20 ALP activity was 
calculated from a standard ρNP curve and all values 
were normalized against total protein concentration 
determined by Lowry’s method.21
Evaluation of matrix mineralization
Von Kossa staining was applied to detect the 
presence of phosphate, an indicator of extracellular 
matrix mineralization. ASCs and MC3T3-E1 (2x104 
cells/well) were cultured in 96-well plates for 21 
days. Cells were fixed for 1h with 3% (v/v) aqueous 
paraformaldehyde, stained with 1% (w/v) silver nitrate 
under light exposure for 1h, and counterstained with 
eosin.20
Total calcium was quantified on ASCs and MC3T3-E1 
(2x104 cells/well), cultured in 96-well plates for 5, 12, 
23, and 32 days, using a Calcium Assay Kit.20
qPCR
ASCs and human osteoblasts (9.4x104 cells/
well) were cultured in 24-well plates for 7, 14, 21, 
and 28 days. Total RNA was isolated using Trizol® 
reagent, according to the manufacturer’s instructions. 
RNA concentration was estimated by NanoVue (GE 
Healthcare, Little Chalfont, Buckingmshire, UK). 
Only samples with an optical density ratio at 260 
nm/280 nm greater than 1.8 were used. After 
DNAse treatment, total RNA (1 µg) was transcribed 
into cDNA using oligo dT primers and SuperScript, 
according to the manufacturer’s instructions. PCR 
amplifications were performed in a 20 µl reaction 
mix containing 10 ng cDNA, 50 nM primers, and 10 
µl Power SYBR1 Green PCR Master Mix. Comparative 
cycle threshold (Ct) method was used to quantify 
changes in osteocalcin and osteonectin gene 
expression between control (human osteoblasts) and 
treated ASCs. Fold change in transcript levels was 
calculated according to the 2-∆∆Ct method, where 
∆∆Ct = (∆Ct control) - (∆Ct treatment) and ∆Ct = (Ct 
target gene) - (Ct internal control; ribosomal 18s). 
The following primers were used: Osteocalcin mRNA 
relative expression: 5’-AGGGCAGCGAGGTAGTGAAG-3’ 
(forward); 5’-AACTCGTCACAGTCCGGATTG-3’ 
( reverse).  Osteonect in mRNA express ion: 
5’-CGGGTGAAGAAGATCCATGAG-3’ (forward); 
5’-CTGCCAGTGTACAGGGAAGATG-3’ (reverse).20
Western blotting
ASCs and MC3T3-E1 (9.4x104 cells/well) were 
cultured in 24-well plates for 7, 14, 21, and 28 
days. Samples (5 µg of protein) were separated 
electrophoretically on SDS/polyacrylamide gel and 
transferred to Immobilon-P membranes (Millipore, 
Danvers, MA, USA). After blocking, membranes 
were incubated overnight using anti-Smad1 (05-
1459, 1:500), or -Smad4 (04-1033, 1:1000), or 
-phosphorylated Smad1/5/8 (AB3848, 1:500), or 
-BMP-4 (MAB1045, 1:500), or -BMP-7 (MAB4350, 2 
µg /ml), or -β actin (04-1116, 1:2000) antibodies. 
After incubation with each corresponding secondary 
antibody, the Enhanced chemiluminescence Pierce 
ECL substrate was used for detection, according to the 
manufacturer’s protocol. Expression of each protein 
was normalized against β-actin. Phosphorylated 
Smad1/5/8 was normalized against Smad1. Band 
intensities were quantified using the ImageJ software 
(National Institute of Health, USA).20
Signaling pathways analysis
Calcium, proteins (ALP, Smad1, Smad4, 
phosphorylated Smad1/5/8, BMP4, and BMP7) and 
mRNAs (osteonectin and osteocalcin), designed as 
analytes, were analyzed using Ingenuity Pathways 
Analysis (IPA®, QIAGEN Redwood City, USA, www.
ingenuity.com) to determine cellular pathways and 
biological functions impacted by BMP-2, RA, or 
BMP2+RA supplementation at all evaluated time points. 
All analytes with their corresponding quantification 
values, gene ID, and ρ values were uploaded into the 
software to run IPA-core analysis. Overall dysregulated 
analytes (up-regulated and down-regulated; both 
together) were analyzed. Groups were compared to 
each other (designed as observation) by fold change 
of analyte levels. Results identified the canonical 
pathways and biological functions that were most 
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significant to the data set. Right-tailed Fisher’s exact 
test was used to calculate a ρ value that determined 
the probability of each pathway or biological function 
assigned to that data set being caused by chance 
alone. The prediction of activation or inhibition of a 
canonical pathway or biological function was based on 
z-score. IPA® automatically calculates z-scores based 
on differentially expressed analytes in our dataset 
and the information stored in Ingenuity’s Knowledge 
Base.22,23
Statistical analysis
Three independent experiments were performed 
to confirm the reproducibility of the results. Graph 
Pad Software Inc. (San Diego, CA, USA) was used 
for statistical evaluation. ALP activity, calcium 
quantification, mRNA relative expression, and protein 
quantification results from all groups were compared 
through one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test. Differences between 
datasets with ρ<0.05 were considered statistically 
significant. Statistical analyses were performed 
comparing all treatments at each time point separately.
Results
The confirmation that the ASCs used in this 
report were mesenchymal stem cells was previously 
published.19
RA increased ALP activity 
ALP activity peaked for all groups at day 7 of 
culturing, when MC3T3-E1 showed the highest 
quantification level. RA promoted the highest ALP 
activity at all time points (days 7, 14, 21, and 28) 
(ρ<0.001) when compared to BMP-2 and BMP-2+RA 
treatments (Figure 1a).
BMP-2+RA increased calcium deposition at 
extracellular matrix
Von Kossa staining revealed all groups displayed 
detectable extracellular matrix mineralization at day 
21 (Figure 1b1-b5).
Calcium quantification showed no detectable 
deposition at extracellular matrix at day 5 (data 
not shown). At day 12, control MC3T3-E1 showed 
the highest calcium production; among the tested 
groups, BMP-2+RA treatment promoted significantly 
the highest calcium levels (ρ<0.0001). At day 23, OM, 
BMP-2, and MC3T3-E1 demonstrated similar calcium 
levels, which increased significantly when compared 
to RA and BMP-2+RA groups (ρ<0.0001). At day 
32, BMP-2+RA group exhibited the highest calcium 
levels when compared to the test and control groups 
(ρ<0.0005) (Figure 1c).
BMP-2+RA increased osteonectin and 
osteocalcin mRNA expression
At day 7, BMP-2+RA showed the highest osteocalcin 
(ρ=0.0042) and osteonectin (ρ=0.0030) mRNA 
expression levels. There was no difference on 
osteocalcin and osteonectin mRNA expression 
among all groups at days 14 (ρ=0.3317; ρ=0.0983, 
respectively), 21 (ρ=0.1154; ρ=0.4422, respectively), 
and 28 (ρ=0.7041; ρ=0.2414, respectively) (Figure 
2a and Figure 2b).
Expression of osteoblast-related proteins
According to Figure 3, at day 7, BMP-2 treated 
group expressed the highest Smad1 level, followed 
by RA, BMP-2+RA, OM, and MC3T3-E1 groups 
(ρ<0.0001). At day 14, the highest expression was 
demonstrated by BMP-2, followed by MC3T3-E1, BMP-
2+RA, RA, and OM (ρ<0.0001). At day 21, BMP-2 
showed the highest Smad1 expression, followed by RA, 
OM, BMP-2+RA, and MC3T3-E1 (ρ<0.0001). Finally, 
RA demonstrated the highest expression at day 28, 
followed by BMP-2+RA, MC3T3-E1, BMP-2, and OM 
(ρ<0.0001).
Regarding Smad4, control cells MC3T3-E1 
demonstrated the highest expression levels, followed 
by ASCs treated with BMP-2+RA, BMP-2, OM, and RA 
(ρ<0.0001) at day 7. At day 14, BMP-2+RA treatment 
showed the highest expression levels, followed by 
BMP-2, RA, MC3T3-E1, and OM (ρ<0.0001). At day 
21, MC3T3-E1 exhibited the highest expression level 
followed by BMP-2+RA, OM, RA, and BMP-2 treatments 
(ρ<0.0001). At day 28, BMP-2+RA group showed the 
highest Smad4 expression, followed by MC3T3-E1, RA, 
OM, and BMP-2 groups (ρ<0.0001).
MC3T3-E1 exhibited the highest expression of 
phosphorylated Smad1/5/8 at days 7 (ρ<0.001). 
Among the test groups, BMP-2+RA expressed more of 
these proteins at day 7, followed by RA (ρ<0.001). At 
day 14, RA treatment induced the highest expression 
of phosphorylated Smad1/5/8, followed by BMP-2+RA 
(ρ<0.001). There was no expression of these proteins 
in the OM group at day 7, and BMP-2 group at days 
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7 and 14. At day 21, RA treatment exhibited the 
highest phosphorylated Smad1/5/8 level, followed by 
OM and BMP-2 (ρ<0.001), while no expression was 
observed in the BMP-2+RA and MC3T3-E1 groups. 
These phosphorylated Smads were not detected in 
any group at day 28.
Considering BMP-4, no group was able to express 
this growth factor at day 7. At day 14, BMP-2 
demonstrated the highest BMP-4 level, followed by 
RA, BMP-2+RA, MC3T3-E1, and OM (ρ<0.0001). At 
day 21, the OM group exhibited the highest BMP-4 
expression, followed by BMP-2+RA, BMP-2, and RA 
Figure 1- Extracellular matrix evaluation. A) Alkaline phosphatase (ALP) activity expressed as mg of rNitrophenol (rNP) per mg of 
protein per ml at days 7, 14, 21, and 28. Different letters refer to statistically significant differences (r<0.001) (ANOVA/Tukey). Statistical 
analyses were performed comparing all treatments at each time point separately. B) von Kossa staining of ASCs cultured for 21 days. Bar 
= 500 µm. Black areas show the presence of phosphate and indicate extracellular matrix mineralization, suggesting differentiation into 
osteoblasts. Cells were treated with OM (B1), OM supplemented with BMP-2 (B2), OM with RA (B3), or OM supplemented with BMP-2 
and RA (B4). MC3T3-E1 was used as a positive control (B5). Images are representative of three independent experiments; C) Calcium 
quantification expressed as mg per dl at days 12, 23, and 32. Bars represent the mean ± SD of three independent experiments. Different 
letters represent statistically significant differences (r<0.05) (ANOVA/Tukey) among treatments at each time point.
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groups (ρ<0.0001). OM treatment demonstrated 
the highest BMP-4 level, followed by RA, BMP-2, 
MC3T3-E1, and BMP-2+RA at day 28 (ρ<0.0001).
At day 7, the BMP-2 treated group expressed the 
highest BMP-7 amount, followed by BMP-2+RA, RA, 
OM, and MC3T3-E1 groups (ρ<0.0001). The highest 
BMP-7 expression was exhibited by MC3T3-E1, 
followed by BMP-2, RA, OM, and BMP-2+RA at day 
14 (ρ<0.0001). At day 21, BMP-2 demonstrated the 
highest BMP-7 expression, followed by BMP-2+RA, RA, 
MC3T3-E1, and OM groups (ρ<0.0001). Finally, RA 
showed the highest expression at day 28, followed by 
OM, BMP-2, MC3T3-E1, and BMP-2+RA (ρ<0.0001).
Signaling pathways analysis
IPA® analysis indicated that the major changes in 
BMP signaling pathway occurred at days 14 and 21 
(Table 1). Osteogenic differentiation peaked at day 
14 for the positive control group (MC3T3-E1). When 
compared to the negative control (OM), BMP-2+RA, 
BMP-2, and RA treatments promoted the most BMP 
signaling pathway up-regulation at day 14. At days 7, 
14, and 21, BMP-2 treatment induced BMP signaling 
pathway more strongly than the RA treatment. Overall, 
Figure 2- mRNA relative expressions. ASCs were treated according to the groups: OM (osteogenic medium); BMP-2 (OM and BMP-2); 
RA (OM and retinoic acid, RA); BMP-2+RA (OM, BMP-2, and RA). Results were normalized against human osteoblasts (positive control). 
Different letters represent statistically significant differences among treatments at each time point (ANOVA/Tukey, ρ<0.05). Bars represent 
the mean ± SD of three independent experiments
Figure 3- Expression of osteoblast-related proteins. Proteins expressions evaluated by western blotting at days 7, 14, 21, and 28 of ASCs 
treated according to the groups: OM (osteogenic medium); BMP-2 (OM and BMP-2); RA (OM and retinoic acid, RA); BMP-2+RA (OM, 
BMP-2, and RA). MC3T3-E1 was used as positive control. Bands are representative of three independent experiments. Band intensities 
were quantified. Different letters represent statistically significant differences (r<0.05) (ANOVA/Tukey) among treatments at each time 
point
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among the tested groups, the BMP-2+RA combination 
more actively induced BMP signaling in most of the 
set points (days 7, 14, and 28).
In addition to the identification of signaling pathway 
involved in the osteogenic differentiation, IPA® 
analysis suggested the biological functions influenced 
by the treatments (Table 1). According to these 
results, MC3T3-E1, RA, and BMP-2+RA increased the 
differentiation of bone-forming cells when compared 
to OM at day 14.
Discussion
Despite many efforts, bone repair remains a 
challenge in many cases of oral and maxillofacial 
surgeries. BMP-2 has been clinically applied to 
stimulate osteogenic differentiation of mesenchymal 
stem cells and to promote bone repair. In addition to 
its high cost, BMP-2 use has been related with adverse 
effects.4-6 Given that and the possible use of RA to 
substitute and/or potency BMP-2 effects, this study 
compared the outcomes of BMP-2, RA, and BMP-2+RA 
on in vitro osteogenic differentiation of ASCs and 
evaluated the BMP signaling pathways involved in the 
differentiation process. Among the groups, RA most 
stimulated the ALP activity at days 7, 14, 21, and 28. 
BMP signaling pathway – Day 7 BMP signaling pathway – Day 21
Observation Z-score ρ value Observation Z-score ρ value
OM v MC3T3-E1 0 OM v MC3T3-E1 0
BMP-2 v MC3T3-E1 0 BMP-2 v MC3T3-E1 0
RA v MC3T3-E1 0 RA v MC3T3-E1 0
BMP-2+RA v MC3T3-E1 0 BMP-2+RA v MC3T3-E1 0
BMP-2 v OM 0 BMP-2 v OM 1.342 5.14E-11
RA v OM 0 RA v OM 0.447 5.14E-11
BMP-2+RA v OM 0 BMP-2+RA v OM -1.342 5.14E-11
BMP-2 v RA 1 4.51E-09 BMP-2 v RA 0.447 5.14E-11
BMP-2 v BMP-2+RA -1 4.51E-09 BMP-2 v BMP-2+RA 1.342 5.14E-11
RA v BMP-2+RA -1 4.51E-09 RA v BMP-2+RA 0.447 5.14E-11
BMP signaling pathway – Day 14 BMP signaling pathway – Day 28
Observation Z-score ρ value Observation Z-score ρ value
OM v MC3T3-E1 -2 4.41E-9 OM v MC3T3-E1 0
BMP-2 v MC3T3-E1 0 BMP-2 v MC3T3-E1 0
RA v MC3T3-E1 -1 4.41E-9 RA v MC3T3-E1 0
BMP-2+RA v MC3T3-E1 -1 8.8E-9 BMP-2+RA v MC3T3-E1 0
BMP-2 v OM 1 5.14E-11 BMP-2 v OM 0
RA v OM 2.236 5.14E-11 RA v OM 1 8.8E-9
BMP-2+RA v OM 1.342 4.41E-9 BMP-2+RA v OM 2 8.8E-9
BMP-2 v RA 1 8.8E-9 BMP-2 v RA -1 8.8E-9
BMP-2 v BMP-2+RA -1 8.8E-9 BMP-2 v BMP-2+RA -2 8.8E-9
RA v BMP-2+RA -0.447 5.14E-11 RA v BMP-2+RA 0
DIFFERENTIATION OF BONE-FORMING CELLS at day 14
Observation ρ value Activation 
z-score
Molecules
OM v MC3T3-E1 2.20E-06 -2 Ca2+,SMAD1,SMAD4,SMAD5
RA v OM 1.24E-07 2 Ca2+,SMAD1,SMAD4,SMAD5
BMP-2+RA v OM 1.24E-07 2 Ca2+,SMAD1,SMAD4,SMAD5
Table 1- Relation between the different cell treatments and the BMP signaling pathway indicated by IPA® software at days 7, 14, 21, and 
28. ASCs were treated according to the groups: OM (osteogenic medium); BMP-2 (OM and BMP-2); RA (OM and retinoic acid, RA); 
BMP-2+RA (OM, BMP-2, and RA). MC3T3-E1 was used as positive control. r<0.05 represents statistically significant difference. Positive 
z-score indicates up-regulation (highlighted in orange) and negative z-score implies down-regulation (highlighted in blue) of the signaling 
pathway evidenced by the IPA® software (v=versus)
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BMP-2+RA most stimulated the matrix mineralization 
at days 12 and 32; osteocalcin and osteonectin mRNA 
expression at day 7; Smad4 expression at days 7, 
14, 21, and 28; and phosphorylated Smad1/5/8 
expression at day 7. Additionally, BMP-2+RA promoted 
the highest BMP signaling pathway activation at days 
7 and 14. Furthermore, at day 14, RA and BMP-2+RA 
treatments increased the activation of differentiation 
of bone-forming cells when compared to OM, while 
BMP-2 alone did not demonstrate this capacity.
These results increase the possibility of using RA 
combined with BMP-2 to enhance the osteogenic 
differentiation. Corroborating our results, Wan, et 
al.12 (2006) observed the increase in osteogenic 
differentiation of ASCs with the association of 
BMP-2 and RA. Li, et al.13 (2003) observed that RA 
stimulates chondrocyte differentiation and enhances 
BMP effects. Cowan, et al.14 (2005) demonstrated that 
BMP-2 combined with RA accelerates in vivo bone 
formation. Interestingly, Bi, et al.24 (2018) suggest 
that the combination of RA and BMP2/7 could be 
a novel approach to treat hyperactive osteoclast-
induced bone loss such as in inflammation-induced 
severe osteoporosis and bone loss caused by cancer 
metastasis to bone. Conversely, Hoffman, et al.18 
(2006) verified the attenuation of RA signaling from 
BMP action.
RA exhibited higher ALP activity than BMP-2 and 
BMP-2+RA at all time points, and than positive control 
at most time points. Some studies8,25 also showed 
that RA stimulates ALP activity. Conversely, other 
studies16,17,26 did not observe such stimulation on ALP 
activity by RA. Some reports describe the potentiation 
between RA and BMP-2 on ALP activity8,12,27. Such 
potentiation was not observed in this study.
We performed the von Kossa staining to evaluate 
osteogenic differentiation. In this technique, the stain 
reacts with phosphate in the presence of acidic material 
and does not react with calcium. Despite this method 
being used in several reports, this is not a sensitive 
assay to evaluate mineralization. For this reason, 
we also quantified the calcium at the extracellular 
matrix28. Corroborating other studies9,12, BMP-2 and 
RA potency each other’s effects on calcium secretion. 
Additionally, at the mineral deposition peak (day 32), 
calcium concentration in BMP-2+RA group was higher 
than in the positive control. This cooperation might 
occur due to the inhibition of adipocyte differentiation, 
as previously stated8. In contrast, Bi, et al.27 (2013) 
observed additional matrix mineralization promoted by 
BMP when compared to BMP combinedwithRA.
Osteocalcin and osteonectin are important 
noncollagen bone matrix components considered 
markers of osteoblast mineralization29. Our results 
showed that BMP-2+RA stimulated osteonectin 
and osteocalcin mRNA expression at day 7. Such 
early osteocalcin and osteonectin mRNA expression 
could be connected to the highest mineralization at 
extracellular matrix promoted by the association of 
BMP-2 and RA, even with the low ALP expression 
observed in this group. When studying preadipocytes, 
Skillington, et al.8 (2002) observed that BMP-2, alone 
or combined with RA, was unable to induce neither 
osteocalcin mRNA expression nor extracellular matrix 
mineralization. Wang, et al.15 (2008) verified that 
bone marrow stromal cells treated with RA did not 
enlarge osteonectin mRNA expression. On the other 
hand, other reports25,30 found that RA stimulated 
the osteocalcin mRNA expression. Bi, et al.27 (2013) 
showed fewer osteocalcin expression in cells treated 
with RA combined with BMP-2/7 when compared to 
cells treated with BMP-2/7 only. These different findings 
could be due to the different cell types analyzed. Our 
report is the first to evaluate the effects of BMP+RA 
on osteogenic differentiation of human ASCs.
In addition to evaluating osteogenic differentiation 
of ASCs, we studied the effect of different treatments 
on Smads expression. Classical signaling pathways 
for BMPs begins with the binding of BMP to a dimeric 
complex of transmembrane serine–threonine kinase 
receptors, type I and type II receptors. Type I receptors 
include BMP receptors (BMPRs) -Ia, -Ib, and activin 
receptor type 1 (ACTR1); type II receptors include 
BMPR-II, ACTR2, and -2b. Heteromeric receptor 
complexes comprising type I and II receptors lead to 
ligand-induced phosphorylation of type I receptors. 
Following the activation of this receptor, receptor 
kinases phosphorylate transcription factors Smad1, 5, 
or 8 that subsequently form heteromeric complexes 
with Smad4 and activate the expression of target 
genes in the nucleus31,32. Herein, ASCs treated with 
BMP-2+RA showed more Smad4 expression than cells 
treated with BMP-2 or RA alone. Conversely, ASCs 
treated with BMP-2 exhibited more Smad1 expression 
than RA alone or combined with BMP-2. However, the 
analysis of phosphorylated Smad1/5/8 is much more 
important than Smad1 since phosphorylation indicates 
the activation of these proteins. We showed that 
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BMP-2+RA up-regulated phosphorylated Smad1/5/8 
expressions at the beginning of the differentiation 
process. Moreover, ASCs treated with BMP-2+RA 
demonstrated a similar expression pattern to positive 
control, discontinuing the expression of phosphorylated 
Smads from day 21 onwards, which may be related to 
an osteoblast lineage commitment. The IPA® analysis 
corroborates the molecular mechanism behind the 
cross talk of RA and BMP is the BMP signaling pathway.
The interpretation of osteogenic differentiation 
based on analysis of osteogenic markers separately is 
very challenging due to the difficulty of understanding 
and correlating all results with the whole differentiation 
process. In this study, we applied the IPA® software 
to evaluate the BMP signaling pathways involved in 
osteogenic differentiation and to observe the process 
more comprehensively. IPA® calculates the probability 
that the analytes are involved in particular pathways, 
comparing it to the total number of occurrences of 
those analytes in all function annotation stored in the 
Ingenuity Knowledge Base. We confirmed that both RA 
and BMP-2, alone or combined, used the BMP signaling 
pathway for osteogenic differentiation33. Adams, et al.34 
(2003) showed that RA seemed to stimulate type-X 
collagen gene transcription, partially by stimulating 
the BMP signaling pathway and partially through 
independent mechanisms. Liu, et al.11 (2014) observed 
RA modulated osteogenesis through the Wnt/β-catenin 
signaling pathway. Conversely, Sheng, et al.35 (2010) 
proposed that RA enhances the interaction between 
phosphorylated Smad1 and its ubiquitin E3 ligases, 
resulting in phosphorylated Smad1 ubiquitination and 
proteasomal degradation, suggesting a mechanism 
through which RA suppresses BMP/Smad signaling. 
Zhang, et al.36 (2017) demonstrated that RA signaling 
regulates COL9A1 expression through the BMP2-
WNT4-RUNX1 pathway. These different results may be 
occur because the BMP signaling pathway is cell type-
specific and cell context-dependent, given that Yang, et 
al.33 (2012) studied 143B osteosarcoma cells, Adams, 
et al.34 (2003) evaluated chondrocytes from embryonic 
chick sterna, Liu, et al.11 (2014) employed 3-T3-L1 
preadipocytes, Sheng, et al.35 (2010) evaluated P19C6 
cells, a subclone of mouse embryonic carcinoma, and 
Zhang, et al.36 (2017) studied antler chondrocytes.
We also observed that BMP-2+RA up-regulated 
the BMP signaling pathway when compared to BMP-
2 and RA treatments at days 7 and 14. Conversely, 
at day 21, BMP-2 and RA up-regulated the BMP 
signaling pathway when compared to BMP-2+RA. 
The reason for this finding may be related to an 
early osteoblast lineage commitment of ASCs under 
BMP-2+RA treatment, discontinuing the osteogenic 
markers expression, similar to what we suggested in 
the results for phosphorylated Smads. According to 
IPA® results, RA and BMP-2+RA treatments increased 
the activation of differentiation of bone-forming cells 
when compared to the negative control (OM), while 
BMP-2 did not demonstrate this capacity.
Conclusions
Results indicate that BMP-2+RA better induced 
osteogenic differentiation of human ASCs. This finding 
strengthens the possibility of using BMP-2 combined 
with RA to enhance bone repair in oral and maxillofacial 
surgery. Additionally, this combination may enable the 
use of reduced doses of BMP-2, possibly minimizing 
BMP-2-induced adverse effects and treatment costs. 
Future experiments evaluating the capacity of BMP-2 
combined with RA to enhance bone repair in animals 
must be conducted, and further research is required to 
determine the synergism mechanisms between BMP-2 
and RA in bone repair.
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